BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kaida-Yip F, Deshpande K, Saran T, Vyas D. Biosimilars: Review of current applications, obstacles, and their future in medicine. World J Clin Cases 2018; 6(8): 161-166 [PMID: 30148143 DOI: 10.12998/wjcc.v6.i8.161]
URL: https://www.wjgnet.com/2307-8960/full/v6/i8/161.htm
Number Citing Articles
1
Deeksha Joshi, Rubiya Khursheed, Saurabh Gupta, Diksha Wadhwa, Thakur Gurjeet Singh, Sumit Sharma, Sejal Porwal, Swati Gauniyal, Sukriti Vishwas, Sanjay Goyal, Gaurav Gupta, Rajaraman D. Eri, Kylie A. Williams, Kamal Dua, Sachin Kumar Singh. Biosimilars in Oncology: Latest Trends and Regulatory StatusPharmaceutics 2022; 14(12): 2721 doi: 10.3390/pharmaceutics14122721
2
Aqsa Safdar, Muhammad Hammad Butt, Abrar Ahmad, Muhammad Zaman. Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodiesJournal of Oncology Pharmacy Practice 2021; 27(5): 1195 doi: 10.1177/10781552211016083
3
Kritika Gupta, Ranjeet Desai, Ketki Jawade, Dhanashree D. Jagtap, Deepak Modi, Ratnesh Jain, Prajakta Dandekar. Determination of functional similarity of biosimilar H9P2S from an investigational CHO clone with Adalimumab3 Biotech 2022; 12(11) doi: 10.1007/s13205-022-03384-z
4
Shadi Askari, Alireza Ghofrani, Hamed Taherdoost. Transforming Drug Design: Innovations in Computer-Aided Discovery for Biosimilar AgentsBioMedInformatics 2023; 3(4): 1178 doi: 10.3390/biomedinformatics3040070
5
Simon W Lam, Kevin Amoline, Christopher Marcum, Mandy Leonard. Healthcare system conversion to a biosimilar: Trials and tribulationsAmerican Journal of Health-System Pharmacy 2021;  doi: 10.1093/ajhp/zxab279
6
Xinyi Xu, Shengzhao Zhang, Ting Xu, Mei Zhan, Chen Chen, Chenyu Zhang. Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-AnalysisFrontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.880090
7
Ying Gao, David Gervais. Overcoming challenges of improving legacy biopharmaceutical processesJournal of Chemical Technology & Biotechnology 2021; 96(5): 1141 doi: 10.1002/jctb.6687
8
Alexey V. Samtsov, Andrey L. Bakulev, Vladislav R. Khairutdinov, Muza M. Kokhan, Tat’yana V. Korotaeva, Iskander K. Minullin, Olga A. Vylegzhanina, Valery V. Dubenskiy, Bulat V. Khalilov, Alkes A. Khotko, Olga S. Zykova, Irina V. Chumachenko, Alexander M. Lukyanov, Antonina V. Artemeva, Polina P. Pukhtinskaia, Yuanyuan Wang. Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trialPLOS ONE 2022; 17(2): e0263214 doi: 10.1371/journal.pone.0263214
9
Douglas J. Rupert, Alyssa M. Jordan, Marina A. Ziemian, Rachel M. Brown, Neil S. Fleming, R. Craig Lefebvre. Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative StudyBioDrugs 2022; 36(5): 645 doi: 10.1007/s40259-022-00545-7
10
John Hair, Thomas Maryon, Cristian Lieneck. Identification of Barriers Preventing Biosimiliar Oncology Medication AdoptionMedicina 2022; 58(11): 1533 doi: 10.3390/medicina58111533
11
Shubha Bhat, Sarah Altajar, Divya Shankar, Toni Zahorian, Regine Robert, Taha Qazi, Bhavesh Shah, Francis A. Farraye. Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-DyybJournal of Managed Care & Specialty Pharmacy 2020; 26(4): 410 doi: 10.18553/jmcp.2020.26.4.410
12
Jennifer Fenna, Daniel McCormack, Sophie Kitchen, Diana Martins, Tara Gomes, Mina Tadrous. Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, CanadaJournal of Managed Care & Specialty Pharmacy 2021; 27(4): 444 doi: 10.18553/jmcp.2021.27.4.444
13
Mohamed Izham Mohamed Ibrahim, Ahmed Awaisu. Global Pharmaceutical Policy2020; : 53 doi: 10.1007/978-981-15-2724-1_3
14
Peter J. Choi, Thomas I−H. Park, Elizabeth Cooper, Mike Dragunow, William A. Denny, Jiney Jose. Heptamethine Cyanine Dye Mediated Drug Delivery: Hype or HopeBioconjugate Chemistry 2020; 31(7): 1724 doi: 10.1021/acs.bioconjchem.0c00302
15
NayanaHitesh Patel, NiketH Patel, MolinaNiket Patel, HarshaK Bhadarka, KairaviSunilkumar Vyas. Clinical outcomes in patients receiving originator follitropin alfa and follitropin alfa biosimilars in real-world clinical practice: A retrospective studyJournal of Human Reproductive Sciences 2023; 16(2): 148 doi: 10.4103/jhrs.jhrs_37_23
16
Yeong Wook Song, Yong-Beom Park, Jinseok Kim. LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritisExpert Opinion on Biological Therapy 2021; 21(1): 1 doi: 10.1080/14712598.2020.1701650
17
Bárbara Peliçário Vargas, Marcel Henrique Marcondes Sari, Luana Mota Ferreira. Trastuzumab in Breast Cancer Treatment: The Era of BiosimilarsAnti-Cancer Agents in Medicinal Chemistry 2022; 22(14): 2507 doi: 10.2174/1871520622666220302114313
18
Juan David Rosas Cabrera, Carlos Andrés Díaz Rodríguez. Pichia pastoris as a biological platform to produce recombinant proteins: relevance for development of biotechnological products in ColombiaRevista de la Facultad de Ciencias 2021; 10(1): 20 doi: 10.15446/revfaccienc.v10n1.86805
19
Viraj A Shinde, Ramanand Patil, Prasan Bhandari, Prachitee Borkar, Shraddha Yadav. A Pharmacoeconomic Outlook of the Biological Drugs Marketed in India: A Cost Variance AnalysisCureus 2023;  doi: 10.7759/cureus.33943
20
Obinna N. Obianom, Olanrewaju O. Okusanya, Justin Earp, Theingi M. Thway. A Simulation Approach to Evaluate the Impact of Patterns of Bioanalytical Bias Difference on the Outcome of Pharmacokinetic Similarity StudiesClinical Pharmacology & Therapeutics 2020; 108(1): 107 doi: 10.1002/cpt.1767
21
J. Posner, P. Barrington, T. Brier, A. Datta-Mannan. Concepts and Principles of PharmacologyHandbook of Experimental Pharmacology 2019; 260: 81 doi: 10.1007/164_2019_323
22
Rachel N. Israilevich, Kannan Sharma, Matthew R. Starr. Biosimilars for Retinal Diseases: A Review of the LiteratureInternational Ophthalmology Clinics 2024; 64(1): 129 doi: 10.1097/IIO.0000000000000509
23
Xiaoying Chen, Cheryl Li, Reginald Ewesuedo, Donghua Yin. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancerCancer Chemotherapy and Pharmacology 2019; 84(1): 83 doi: 10.1007/s00280-019-03850-1
24
Nikola A. Ivica, Colin M. Young. Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)Healthcare 2021; 9(8): 1062 doi: 10.3390/healthcare9081062
25
Ran Jin, Silvia Kruppert, Florian Scholz, Isabelle Bardoulat, Khalil Karzazi, Greg Kricorian, James L. O’Kelly, Walter Reinisch. Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel diseaseTherapeutic Advances in Gastroenterology 2024; 17 doi: 10.1177/17562848231222332
26
Quentin Jarrion, Brahim Azzouz, James Robinson, Damien Jolly, Catherine Vallet, Thierry Trenque. Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitalsTherapies 2022; 77(4): 467 doi: 10.1016/j.therap.2021.10.012
27
Sofia Konstantinidou, Angeliki Papaspiliou, Eleni Kokkotou. Current and future roles of biosimilars in oncology practice (Review)Oncology Letters 2019;  doi: 10.3892/ol.2019.11105
28
Manvi Singh, Pratima R. Solanki. Biomedical Product and Materials Evaluation2022; : 275 doi: 10.1016/B978-0-12-823966-7.00007-4